Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Adaptimmune Therapeutics (NASDAQ: ADAP), a cell therapy company focused on solid tumor cancers, has scheduled its Q4 and Full Year 2024 financial results and business updates announcement for Thursday, March 20, 2025, before US markets open.
The company will host a live webcast at 8:00 a.m. EDT on the same day. Investors can access the press release through Adaptimmune's corporate website's investor section and join the webcast at https://www.gowebcasting.com/13966. Call-in options are available at 1-833-821-0158 (US/Canada) or 1-647-846-2266 (International), with participants advised to dial in 5-10 minutes before the scheduled start.
Adaptimmune Therapeutics (NASDAQ: ADAP), un'azienda di terapia cellulare focalizzata sui tumori solidi, ha programmato l'annuncio dei risultati finanziari del Q4 e dell'Anno Completo 2024 e aggiornamenti aziendali per giovedì 20 marzo 2025, prima dell'apertura dei mercati statunitensi.
L'azienda ospiterà un webcast dal vivo alle 8:00 a.m. EDT lo stesso giorno. Gli investitori possono accedere al comunicato stampa attraverso la sezione investitori del sito web aziendale di Adaptimmune e partecipare al webcast su https://www.gowebcasting.com/13966. Sono disponibili opzioni di chiamata al 1-833-821-0158 (US/Canada) o 1-647-846-2266 (Internazionale), con i partecipanti che sono invitati a chiamare 5-10 minuti prima dell'inizio programmato.
Adaptimmune Therapeutics (NASDAQ: ADAP), una empresa de terapia celular centrada en los cánceres de tumores sólidos, ha programado el anuncio de sus resultados financieros del Q4 y del Año Completo 2024 y actualizaciones empresariales para el jueves 20 de marzo de 2025, antes de la apertura de los mercados en EE. UU.
La empresa llevará a cabo una transmisión en vivo a las 8:00 a.m. EDT el mismo día. Los inversores pueden acceder al comunicado de prensa a través de la sección de inversores en el sitio web corporativo de Adaptimmune y unirse a la transmisión en https://www.gowebcasting.com/13966. Las opciones de llamada están disponibles al 1-833-821-0158 (EE. UU./Canadá) o 1-647-846-2266 (Internacional), aconsejando a los participantes que llamen de 5 a 10 minutos antes del inicio programado.
Adaptimmune Therapeutics (NASDAQ: ADAP), 고형 종양 암에 중점을 둔 세포 치료 회사는 2024년 4분기 및 연간 재무 결과 및 비즈니스 업데이트 발표를 2025년 3월 20일 목요일 미국 시장 개장 전에 예정했습니다.
회사는 같은 날 오전 8시 EDT에 라이브 웹캐스트를 진행합니다. 투자자는 Adaptimmune의 기업 웹사이트 투자자 섹션을 통해 보도 자료에 접근하고 https://www.gowebcasting.com/13966에서 웹캐스트에 참여할 수 있습니다. 전화 연결 옵션은 1-833-821-0158 (미국/캐나다) 또는 1-647-846-2266 (국제)에서 제공되며, 참가자는 예정된 시작 5-10분 전에 전화할 것을 권장합니다.
Adaptimmune Therapeutics (NASDAQ: ADAP), une entreprise de thérapie cellulaire axée sur les cancers des tumeurs solides, a prévu l'annonce de ses résultats financiers pour le Q4 et l'Année Complète 2024 ainsi que des mises à jour commerciales pour jeudi 20 mars 2025, avant l'ouverture des marchés américains.
L'entreprise organisera un webcast en direct à 8h00 EDT le même jour. Les investisseurs peuvent accéder au communiqué de presse via la section investisseurs du site web de l'entreprise Adaptimmune et rejoindre le webcast à l'adresse https://www.gowebcasting.com/13966. Des options de connexion téléphonique sont disponibles au 1-833-821-0158 (États-Unis/Canada) ou 1-647-846-2266 (International), avec des participants invités à appeler 5 à 10 minutes avant le début prévu.
Adaptimmune Therapeutics (NASDAQ: ADAP), ein Unternehmen für Zelltherapie, das sich auf solide Tumoren konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse für Q4 und das gesamte Jahr 2024 sowie Unternehmensupdates für Donnerstag, den 20. März 2025, vor der Eröffnung der US-Märkte angesetzt.
Das Unternehmen wird am selben Tag um 8:00 Uhr EDT eine Live-Webcast veranstalten. Investoren können über den Investorenbereich der Unternehmenswebsite von Adaptimmune auf die Pressemitteilung zugreifen und dem Webcast unter https://www.gowebcasting.com/13966 beitreten. Telefonische Teilnahmeoptionen sind unter 1-833-821-0158 (USA/Kanada) oder 1-647-846-2266 (International) verfügbar, wobei die Teilnehmer gebeten werden, 5-10 Minuten vor dem geplanten Beginn anzurufen.
- None.
- None.
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.
The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13966. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-846-2266 (International). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244379
FAQ
When will Adaptimmune (ADAP) release its Q4 and Full Year 2024 earnings?
How can investors join Adaptimmune's (ADAP) Q4 2024 earnings call?
What time is Adaptimmune's (ADAP) Q4 2024 earnings webcast?
Where can investors find Adaptimmune's (ADAP) Q4 2024 earnings press release?
